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Outcomes variables for research on sepsis have centered on mortality and changes in the host
immune response. However, a recent task force (Sepsis-3) revised the definition of sepsis to “lifethreatening organ dysfunction caused by a dysregulated host response to infection.” This new
definition suggests that human studies should focus on organ dysfunction. The appropriate criteria
for organ dysfunction in either human sepsis or animal models are, however, poorly delineated,
limiting the potential for translation. Further, in many systems, the difference between
“dysfunction” and “injury” may not be clear. In this review, we identify criteria for organ
dysfunction and/or injury in human sepsis and in rodents subjected to cecal ligation and puncture
(CLP), the most commonly used animal model of sepsis. We further examine instances where
overlap between human sepsis and CLP is sufficient to identify translational endpoints. Additional
verification may demonstrate that these endpoints are applicable to other animals and to other
sepsis models, for example, pneumonia. We believe that the use of these proposed measures of
organ dysfunction will facilitate mechanistic studies on the pathobiology of sepsis and enhance
our ability to develop animal model platforms to evaluate therapeutic approaches to human sepsis.
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INTRODUCTION
Translational research is dependent on the 2-way conduit connecting bench and bedside. In
this paradigm, the characteristic features and common outcomes of a disease, syndrome or
disorder are recognized in patients. A model system is constructed, most often in an animal.
The model is then used to explore the underlying pathobiology of the disorder, and perhaps
to preliminarily assess potential therapeutic approaches. If successful, these interventions
can then be tested in patients and their effect on outcomes determined. Clearly, success is
critically dependent on the correlation between animal model and human disorder. It is also
essential that assessment tools and outcomes measurements in animals have human
correlates. And, there are few disorders where this imperative is more important than in
sepsis.
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The first formal definition of the clinical syndrome we call sepsis was developed by a
consensus conference convened in 1991 (1). The participants identified sepsis as “the
systemic inflammatory response to infection.” “Systemic inflammation” was clinically
identified via the criteria that comprise the “Systemic Inflammatory Response Syndrome”.
Ten years later a second consensus conference affirmed the definition and expanded the list
of clinical criteria (Sepsis-2) (2). Over a similar period, cecal ligation and puncture (CLP) in
rodents (and, on occasion, larger animals) emerged as the most-frequently used animal
model of sepsis (3). The approach has been extensively refined over the years (4). The use of
CLP and other models has provided a great deal of insight into the pathobiology of sepsis.
These models have not, however, resulted in the development of clinically useful
interventions. Simply put, despite in excess of 150 randomized clinical trials of therapies for
sepsis, many first tested in animal models, no specific, clinically effective intervention has
been identified (5). The failure to translate findings from CLP to clinical sepsis has limited
confidence in the use of animal models for this deadly and common disorder.

Author Manuscript

An important potential contributor to our inability to translate therapies developed in
animals to human sepsis may lie in the identification of sepsis as “infection +
inflammation.” This approach has led to a focus on immune/inflammatory markers, most
often cytokines. However, “systemic inflammation” may be present in many conditions,
including uncomplicated infection. Compounding this issue is a concern regarding
correlations between immune responses in rodents and humans (6). In addition, mortality
has been the most commonly used outcome variable in animal studies and, indeed, in most
clinical trials. But improved clinical support of critically ill patients has shifted the focus
away from simple survival. Indeed, reduced mortality has uncovered a substantial cohort of
sepsis survivors who are plagued by persistent abnormalities in organ function, particularly
in cognition (7–10). Limited studies have demonstrated similar abnormalities in long-term
survivors of CLP (11, 12).
Fortunately, there is a readily available remedy. The 3rd consensus conference on the
definition of sepsis (Sepsis-3) redefined sepsis as “life-threatening organ dysfunction caused
by a dysregulated host response to infection” (13). This new formulation emphasizes that
sepsis is more than an immunological disorder. Although the immune system is indeed a
profoundly important element of the “dysregulated host response”, the Sepsis-3 definition
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posits that the defining characteristic of sepsis is organ dysfunction rather than systemic
inflammation. Thus, it is logical that organ dysfunction (perhaps including dysfunction in
the “immune organ”) be used as an endpoint in studies on sepsis in patients and in animal
models (14). Indeed, function in some organ systems can be measured in both patients with
sepsis and mice subjected to CLP, providing an enhanced ability to make comparisons and
seek correlations. In most systems, however, the terms “dysfunction” and “injury” are used
interchangeably. Clearly, the two are not equivalent; dysfunction may not reflect
demonstrable injury whereas injury does not necessarily lead to dysfunction. Often,
however, it is by recognizing that the other can be identified. In general, dysfunction can be
identified in vivo whereas injury requires either examination of tissue or the existence of a
validated biomarker. Obtaining tissue is often problematic; biopsy may be life-threatening in
coagulopathic patients and is technically difficult in small animals, which are often
sacrificed to allow tissue sampling. Nonetheless, seeking commonalities between feasible
measurements of dysfunction or injury between human sepsis and animal models of the
disorder offers a promising avenue from the development of translatable therapies.
Therefore, in this review, we identify measures of organ dysfunction and/or injury in human
sepsis and in rodents subjected to CLP, the most commonly used animal model. Where
correlations are possible, they are identified. Where limited commonality exists, we
emphasize the opportunity to either seek correlations between existing variables or to seek
new, more applicable measures.

APPROACH

Author Manuscript

We undertook a comprehensive review of the literature using PubMed. We surveyed articles
published between Jan 1, 2000 and the present and used the search terms “Sepsis-3, sepsis,
organ dysfunction, organ injury, human, mice, rats, cecal ligation and puncture, and murine
model.” We sought to identify metrics of dysfunction and/or injury in each of the systems
discussed below. Selected articles were reviewed and commonalities and correlations
between human and animal data were identified. Sections were generated on the basis of the
following template.

Author Manuscript

•

Clinical presentations/quantifiable measures of organ dysfunction/injury in
patients with sepsis.

•

Quantifiable measures of organ dysfunction/injury following CLP.

•

Correlations between measures used in clinical sepsis and those used in CLP.

•

Indication of areas was additional investigation might identify currently
unrecognized correlations and commonalities.

•

Specific limitations and caveats, where applicable.

•

Tabulated recommendations for parameters to be assessed in animals subjected
to CLP.
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RESULTS
Measures of dysfunction/injury in individual organ systems are detailed below. Table 1
contains a compendium of measures of organ dysfunction in human sepsis and following
CLP in rodents.

CARDIAC DYSFUNCTION FOLLOWING CECAL LIGATION AND PUNCTURE
Clinical presentation/quantifiable measures of organ dysfunction/injury in patients with
sepsis
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The defining characteristics of cardiovascular dysfunction in human sepsis are vasodilatation
and myocardial depression. This latter can be definitively identified using echocardiography.
Specific indices include decreased shortening in both long and transverse axes and in
contraction velocity (15, 16). The net functional result may be a depressed ejection fraction
(EF) and circulatory inadequacy (16) but both are influenced by fluid resuscitation.
Incomplete resuscitation is associated with modest increases in heart rate (HR), decreases in
systolic (SVP) or mean arterial blood pressure (MAP) and central venous pressure (CVP),
elevations in pulmonary artery pressure (PAP) (17). HR changes may result in an increase in
cardiac output (CO) despite a low-to-normal stroke volume (SV) (16). With resuscitation,
SVP and MAP decrease, CVP and PAP become quite elevated and calculated vascular
resistance reflects a profound loss of systemic tone. SV and CO may increase substantially
(18). The increase in SV usually reflects dramatic left ventricular (LV) dilation and an
increase in LV end-diastolic volume (LVEDV) that may compensate for the reduced EF (19).
Some correction of blood pressure may occur in the terminal phase of sepsis, but patients
become bradycardic and LV dysfunction may progress to outright failure (20). In recovery,
EF, HR, MAP, CVP, PAP, and SV normalize and resuscitation fluid and interstitial edema are
eliminated. Some myocardial depression may persist and, in extreme cases, never fully
resolve (16). Importantly, all cited parameters can be serially measured with
echocardiography.
Measurable abnormalities following cecal ligation and puncture in rodents

Author Manuscript

Although myocardial depression remains the hallmark of cardiac dysfunction in both CLP
and human sepsis, the presentations differ. Specifically, rodents develop bradycardia
following CLP, returning to normal only in animals that survive and recover. MAP and CVP
in mice reflect resuscitation, whereas PAP is elevated. Use of speckle-tracking
echocardiography can identify early systolic and diastolic dysfunction analogous to changes
in shortening along both axes and reduced contraction velocity (21) (Capone C, Fernandes T,
Abraham M, Taylor M, Deutschman C, unpublished observations).
Correlations between changes induced by clinical sepsis and cecal ligation and puncture
As stated, contractility in both humans and rodents is easily identified using
echocardiography. The effects of human sepsis and murine CLP on SV, EF, and CO may
differ but echocardiographic parameters of systolic dysfunction—longitudinal and
circumferential shortening/strain, conduction velocity—appear to correlate (22, 23).
Importantly, measurements in mice are altered by the need for anesthesia, also a myocardial
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depressant. These parameters can be quantified from echocardiography using readily
available software, eliminating variability among echocardiographers.
Recommendations
•

Cardiac dysfunction following CLP should be quantified using echocardiography
with particular emphasis on parameters of systolic dysfunction, especially strain
and fractional shortening.

•

Changes in SV and CO may or may not correlate with findings in human sepsis
but should be followed.

LIMITATIONS AND CAVEATS
Author Manuscript

Echocardiographic measurements may sometimes be subjective and dependent on technical
experience of the clinical examiner.

LUNG DYSFUNCTION FOLLOWING CECAL LIGATION AND PUNCTURE
Clinical presentations/quantifiable measures of organ dysfunction/injury in patients with
sepsis
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The Acute Respiratory Distress Syndrome (ARDS) is a common and often deadly form of
pulmonary dysfunction in human sepsis and other inflammatory disorders. ARDS is
complex and involves dysregulation and injury in many different cells, pathways, and
processes (24). Dysfunction is primarily reflected in abnormal gas exchange and, following
the initiation of mechanical ventilation, changes in lung volumes and compliance.
Hypoxemia and abnormalities in ventilation/perfusion matching are defining characteristics.
Indeed, severity is often quantified on the basis of the magnitude of hypoxemia as reflected
in the PaO2/FiO2 ratio (Table 2) (25). As fatigue develops, initial hypocarbia that results
from tachypnea quickly gives way to elevations in PaCO2. Pulmonary artery pressure rises,
often to extremes. Increases in extravascular lung water (edema), both interstitial and
alveolar, result from enhanced pulmonary vascular permeability, with loss of aerated lung
tissue (25). These latter changes are reflected in decreases in lung compliance and loss of
functional reserve capacity (FRC). Injury is reflected in broncho-alveolar lavage (BAL) fluid
that contains inflammatory cells and cytokines, shed type I pulmonary epithelial cells, other
evidence of cellular debris and high levels of protein. In addition to the primary disorder,
management may also contribute to the pathobiology of ARDS. Positive pressure
mechanical ventilation alone causes lung injury (ventilator-induced lung injury [VILI]) (26),
whereas fluid restriction may be problematic because it effects the need to optimize
perfusion in other organs and tissues. Thus, it is often impossible to determine what
abnormalities represent sepsis-induced lung injury, what role is played by fluid
administration, and what changes reflect VILI (27).
Measurable abnormalities following cecal ligation and puncture
CLP-induced changes on the lungs of mice and rats mimic, to some degree, the changes seen
in clinical ARDS (28, 29). Animals develop hypoxemia, initially with hypocarbia but
eventually with a respiratory acidosis (30–33). Broncho-alveolar lavage reveals an intense
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inflammatory infiltrate, primarily of neutrophils, elevated levels of TNF-α, IL-1β, and IL-6,
and an increase in detached pneumocytes and other cellular debris. Most other abnormalities
are identified histologically or using homogenates of lung tissue. Initial changes include
interstitial edema, a neutrophilic infiltrate, and shed epithelial cells in the alveolar space
(34). Later abnormalities include airway edema, alveoli filled with cellular debris, white
blood cells and proteinaceous fluid, overgrowth of type II pneumocytes in areas where type I
cell loss has denuded the basal lamina, and eventual patchy consolidation. Fluid, sodium and
protein leak into the airways (33). Studies on type I cells and gap junctions reveal impaired
transport of salt and water out of airways (28). Increased lung water may be quantified using
wet/dry weights (35). Ultimately there is progression to intra-alveolar inflammation or
hyaline membrane deposition, important developments in the pathogenesis of human ARDS
(33).

Author Manuscript

Correlations between changes induced by clinical sepsis and cecal ligation and puncture
Although a number of ARDS-associated abnormalities can be determined in both septic
patients and mice subjected to CLP, most are nonspecific. In part, this limitation reflects the
fact that ARDS is induced by disorders other than sepsis. Blood gas changes will be present
in virtually any lung disorder. BAL findings of protein, neutrophil accumulation, cytokines,
and detached pneumocytes are near-universal findings in ARDS but are by no means
pathognomonic. More characteristic abnormalities require either airway access (ie,
endotracheal intubation) which is not the norm in rodents and other small animals, or
histologic analysis, which is possible in euthanized animals but problematic in patients with
ARDS. The use of some tests (eg, MRI scanning, flux of salt, and water into the alveolar
space) that can be measured in both patients and rodents is limited by expense and the need
for specialized equipment (36–38).

Author Manuscript

Recommendations
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•

The criteria that comprise the Berlin criteria for ARDS—respiratory distress,
radiographic abnormalities, increased lung water not because of cardiac failure
or fluid overload, and hypoxemia as reflected in the PaO2/FiO2 ratio—can be
measured in both clinical sepsis and in rodents subjected to CLP. Practical
considerations, however, suggest that arterial blood gases (including PaO2,
PaCO2, and pH) be obtained in animals subjected to CLP.

•

BAL should be performed, despite the fact that airway access is required. Fluid
should be examined for protein, neutrophils, and detached epithelial cells.

•

The lung wet:dry ratio should be determined to provide an index of extravascular
lung water content. Similar measurements can be made in patients, although
special techniques are required.

•

Histologic changes, easily assessed in animals but not often examined in
patients, should be assessed, as the classic histologic characteristics of human
ARDS have long been established (39). Tissue should be examined for evidence
of cellularity, fibrosis, edema, hyaline membrane formation, and apoptosis/
necrosis.
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Histologic findings in rodents can to some extent be compared with findings on
patient MRI scans. Similarly, MRI scanning of the lung can be performed on
rodents. Thus, lung imaging might become useful in the future (38, 40).

LIMITATIONS AND CAVEAT
All studies on mice are limited by size. In particular, the small blood volume of mice makes
serial blood gas determinations untenable. Similarly, measuring lung compliance or
performing BAL may not be viable or repeatable in such small animals. The use of rats may
overcome some of these limitations. Histologic studies must be made postmortem following
CLP and are not truly feasible in patients. However, it may become possible to correlate the
results with imaging abnormalities, providing a modality that might 1 day be practical in
both patients and rodents.

Author Manuscript

LIVER DYSFUNCTION FOLLOWING CECAL LIGATION AND PUNCTURE
Clinical presentations/quantifiable measures of organ dysfunction/injury in patients with
sepsis
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The clinical presentation of sepsis-induced liver dysfunction reflects underlying
hepatocellular dysfunction. Under normal conditions, activity in these cells involves (but is
not limited to) synthesis of biomolecules that serve as enzymes in pathways that modulate
the substrates used to support organism-wide metabolism, production of proteins involved in
transport and coagulation, detoxification of endogenous and exogenous “poisons”, and 4)
maintenance of acid-base balance (41). Many of these processes are directly altered by
sepsis-induced changes in other systems. For example, hepatic glucose production is
dependent on precursors provided by skeletal muscle or adipose breakdown, or by
metabolism of lactate through the Cori cycle. In addition, hepatocyte activity is hormonedependent and is thus altered by the endocrinopathy of sepsis. As a result, hepatic
gluconeogenesis is elevated relative to basal, unstimulated conditions and is driven in part by
high levels of precursor delivery. However, glucose production is far less than appropriate
for the amount of available substrate and the hormonal milieu that characterize sepsis.
Similarly, serum levels of the transport proteins (prealbumin [transthyretin], transferrin, and
albumin) and of coagulation factors are inappropriately low, due in part to decreased
synthesis. The bio-transformation and conjugation of toxins and drugs for excretion into bile
or urine is impaired. As a result of the impaired detoxification of bilirubin, normal and
abnormal bile acids may be detected in the blood, whereas impaired conjugation and
excretion of bilirubin lead to jaundice. Finally, stressed hepatocytes become “leaky” and
elevated circulating levels of transaminases are very common (41). However, the changes are
nonspecific and may not even reflect cell injury.
Unfortunately, most of these measures are not characteristic of sepsis but rather represent the
hepatic response to any of a number of abnormalities. Further, the liver has tremendous
reserve capacity. Indeed, clotting indices may remain normal with coagulation factor levels
as low as 15% of normal.
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Investigations using mice subjected to CLP exhibit the same alterations in fuel metabolism,
reductions in hepatic protein synthesis, impaired detoxification and decreased membrane
integrity observed in septic humans. In addition, studies using CLP and other models of
sepsis have provided important information about the pathobiology of sepsis-induced liver
dysfunction. Unfortunately, all measurements may reflect not just intrinsic hepatic
dysfunction but also the influence of substrate availability/utilization and endocrine effects.

Author Manuscript

Abnormalities in substrate utilization/synthesis take 2 basic forms; decreased expression of
the genes encoding key proteins, especially gluconeogenic, ketogenic and ureagenic
enzymes (42–46); and attenuated responses to hormones (42–45, 47). Decreases in transport
proteins similarly reflect impaired expression/synthesis but also result from extrahepatic
consumption and leak into the interstitium (48). Decreased levels of coagulation factors may
well reflect reprioritization of protein synthesis as well as increased utilization. Finally,
altered detoxification of endogenous and exogenous toxins and drugs is reflected in
hyperbilirubinemia (49) and may result from changes in the microsomal (P450) system (50)
and in transport both into and out of hepatocytes (51).
Hepatic function is an important determinant of lactate recycling, a process that is impaired
following CLP (47). However, lactate levels also reflect tissue perfusion, increased
glycolysis (“aerobic glycolysis”) (52) that may result from mitochondrial dysfunction (53)
and/or from infused catecholamines (54). Thus, abnormal lactate levels, and even clearance,
are poor indicators of hepatic function. Similarly, increases in serum transaminase levels
occur in cases of “hepatocyte stress” that are not necessarily dysfunctional.

Author Manuscript

Correlations between changes induced by clinical sepsis and cecal ligation and puncture
Most of the clinical indices used to identify liver dysfunction are either nonspecific
(transaminases) or are late biomarkers (bilirubin). Changes in serum levels of transport
proteins, coagulation factors or endogenous toxins such as bilirubin, as noted above, are
altered by nonhepatic factors. Thus, correlations between these findings in patients with
sepsis and mice subjected to CLP may exist but more likely than not are not specific for
hepatic dysfunction. Recent studies, however, suggest that the appearance of normal or
abnormal bile acids in the serum is a more sensitive marker of hepatic dysfunction (41). In
addition, clearance studies on drugs (eg, lidocaine) or toxins may, in the long run, prove to
be most useful. Importantly, the liver has extensive reserve capacity that may limit the value
of biomarkers of any sort in the diagnosis of sepsis-induced liver dysfunction. Ultimately,
biopsies that can be processed for examination of gene expression may be required.

Author Manuscript

Recommendations
•

Although the limitations of most currently used indices of hepatic dysfunction
have been discussed, measurement of transaminases and bilirubin, reflecting
cellular integrity, are nearly universally obtained in clinical sepsis and therefore
should be performed following CLP.
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•

Despite only rarely being examined in humans, analysis of hepatic histology and
gene expression should be determined. Future development of imaging
modalities in patients may provide an avenue for comparison.

•

Hepatic protein synthesis should be investigated. It can be approximated by
measuring serum levels of albumin, transferrin, and transthyretin.

•

Tests with potential value requiring validation that should be considered. These
include lactate clearance, serum bile acid levels, measurement of drug clearance
and impaired gene expression.

LIMITATIONS AND CAVEAT

Author Manuscript

The liver’s immense reserve capacity may limit the ability to truly identify dysfunction or,
absent tissue sampling, injury. Conversely, abnormalities in some frequently—used
measures (eg, serum transaminase levels) may be too sensitive to truly function as
biomarkers. Substrate levels and enzyme expression/activity are subject to changes in
systems other than the liver (eg, skeletal muscle, endocrine). Correlations between changes
in gene expression, determinations of protein abundance and histologic changes in patients
with sepsis and rodents subjected to CLP require validation. Levels of bile acid in serum
have not been examined in rodents (who have different bile acids than humans), whereas
validation in patients is lacking and no correlations between patients and rodents have been
identified.

KIDNEY DYSFUNCTION FOLLOWING CECAL LIGATION AND PUNCTURE
Author Manuscript

Clinical presentations/quantifiable measures of organ dysfunction/injury in patients with
sepsis

Author Manuscript

Sepsis is often accompanied by an abrupt, poorly understood decrease in renal function that
is termed sepsis-induced acute kidney injury (SIAKI) (55). Identification of SIAKI is often
problematic. At one time, it was believed that SIAKI resulted from an ischemic injury
secondary to reduced renal perfusion. However, the demonstration of SIAKI in
normotensive patients, often in the presence of increased renal blood flow (RBF) coupled
with infrequent demonstration of post mortem ischemic injury in patients with SIAKI cast
doubt on this hypothesis (56, 57). SIAKI is characterized by a decrease in the glomerular
filtration rate (GFR) and/or urine output but these measures incompletely reflect renal
function. The use of serum creatinine levels to quantify changes in GFR is compromised by
decreased creatinine production in skeletal muscle and high-volume intravenous fluid
administration (58). Thus, seemingly small increases in creatinine may not reflect a
precipitous loss of renal function (58). In addition, SIAKI epitomizes the difficulties in
distinguishing between functional decline and actual injury (59, 60). This discrepancy makes
it difficult to separate maladaptive renal dysfunction from adaptive reductions in
performance. Indeed, it has been suggested that recovery of function, rather than the severity
of decline, maybe the most important prognostic factor (61). To address these challenges,
experts in SIAKI have examined biomarkers for their ability to distinguish renal injury from
renal functional decline (often called renal “stress”) (55). The currently accepted paradigm
postulates that SIAKI originates with a DAMP-induced injury in the early proximal tubule.
Shock. Author manuscript; available in PMC 2021 March 23.
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The effects of injury are amplified by local inflammation, microvascular abnormalities,
metabolic downregulation and mitochondrial dysfunction (60). Ultimately, these
abnormalities lead to cell-cycle arrest at the G1-S checkpoint that reduces GFR. At what
point injury becomes functionally important, that is, at what point “dysfunction” develops, is
unclear. Importantly, not all renal dysfunction in clinical sepsis is the result of SIAKI.
Indeed, septic patients are at high risk for renal ischemia, microangiopathy, and/or iatrogenic
nephrotoxicity.

Author Manuscript

There is no gold-standard for diagnosing SIAKI. The current Kidney Disease: Improving
Global Outcomes (KDIGO) guidelines recommend identifying acute kidney injury (AKI)
based on changes in serum creatinine, urine output, and the need for renal replacement
therapy (62), grading the disorder into 3 stages that have short and long-term prognostic
validity. To account for premorbid status, only changes in creatinine and urine output from
baseline, and not absolute levels, are considered (62). As a surrogate for the early proximal
tubular injury that, per current theory, initiates SIAKI, KDIGO criteria include biomarkers
such as serum levels of Kidney Injury Molecule-1 (KIM-1) and neutrophil gelatinaseassociated lipocalin (NGAL) (63, 64). Renal stress is quantified using serum levels of
insulin-like growth factor-binding protein-7 (IGFBP7) and tissue-inhibitor of
metalloproteinases-2 (TIMP2) (65). The fact that these markers often rise before changes in
creatinine and urine output become clinically evident underscores the inability to identify the
point where “injury” and “stress” give way to “dysfunction.” The Food And Drug
Administration recently approved use of the TIMP2/IGFBP7 ratio as an index of AKI risk; a
ratio <0.3 indicates very low risk whereas a value >2.0 suggests a high probability of
developing AKI (66, 67).

Author Manuscript

Measurable abnormalities following cecal ligation and puncture

Author Manuscript

Histopathologic abnormalities in CLP-induced AKI include an absence of acute tubular
necrosis, patchy foci of heterogeneous tubular injury, indicated by apical vacuolization and
minimal apoptosis (60). The presence of ischemic injury suggests inadequate resuscitation
(68–70). The stress indicators TIMP2 and IGFBP7 can be measured in urine or using
immunohistochemistry (71). The injury markers KIM-1 and NGAL can be measured in
urine, serum, and/or immunohis-tochemically (70). KIM-1 is likely a better marker in CLP
because it is specific to the proximal tubule, is expressed only during injury, and persists
until the cellular injury resolves (72). GFR following CLP has been determined using
clinically relevant but somewhat unreliable surrogates such as creatinine, cystatin C or
plasma inulin clearance (73). Other quantifiable abnormalities include assessments of RBF
(74, 75). Although many measures have been used following CLP (76), heterogeneous
microvascular dysfunction and preserved overall RBF are characteristic of SIAKI.
Correlations between changes induced by clinical sepsis and cecal ligation and puncture
Clinically accepted measures of SIAKI correlate variably with findings following CLP. The
most commonly measured clinical indices that readily translate to CLP include serum
creatinine and BUN concentrations. Urine output can also be compared. In contrast,
histopathology is often analyzed following CLP but is rarely available in clinical settings.
Biomarkers such as KIM-1, NGAL, IGFBP7, and TIMP2 can be measured in both patients
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and rodents; small urine volumes in rodents favor the use of serum levels. Detection of
biomarkers using immunohistochemistry on fixed tissue sections is feasible following CLP
but not in patients. Renal hemodynamics in clinical sepsis and following CLP are similar but
their measurement may be limited by technical concerns. For example, interpretation of
renal ultrasonography (US) in clinical sepsis may be problematic but findings are readily
translatable. That said, no currently available evidence support the clinical utility of renal US
in SIAKI.
Recommendations
•

Urine output should be quantified daily.

•

CLP studies should include at least 1 clinically relevant measure from 3 domains.
These are:

Author Manuscript
Author Manuscript

–

A GFR surrogate such as creatinine or cystatin C that can also be
measured in patients. The validity of these proxies can be augmented
using other functional measures, such as BUN and urine output, that are
also routinely clinically determined, and with more direct measures of
GFR. These last, however, are rarely measured in patients.

–

At least 1 injury biomarker—KIM-1 (our preference) or NGAL—
measured in urine, serum, or using histopathology. These markers can
also be determined in patients, and it is to be hoped that their clinical
use will increase in the near future.

–

Model verification—some evidence that the injury is not secondary to
ischemia. This can be accomplished via demonstration of
histopathologic findings classical for SIAKI or by showing that RBF is
preserved. Although demonstrating absence of ischemic injury is
currently problematic in clinical practice, it is essential in model
systems.

LIMITATIONS AND CAVEAT
Small volumes in rodents limit the measurement of urine output or determination of
biomarkers in urine. In addition, urine collection requires the use of metabolic cages. As
mentioned, the relationship between actual dysfunction and “stress” markers (TIMP2,
IGFBP7) is somewhat controversial and has not been validated in rodents. Finally, it is
currently difficult to rule out the presence of ischemic injury in patients, where tissue is not
available.

Author Manuscript
Shock. Author manuscript; available in PMC 2021 March 23.

Abraham et al.

Page 12

Author Manuscript

GASTROINTESTINAL TRACT DYSFUNCTION FOLLOWING CECAL
LIGATION AND PUNCTURE
Clinical presentations/quantifiable measures of organ dysfunction/injury in patients with
sepsis
Under nonpathologic conditions, the GI tract serves several essential functions. Involuntary
sequential contractions—peristalsis—propel ingested material from the stomach to the
rectum. The bowel wall is a nearly impenetrable barrier that separates the host from luminal
contents. This barrier allows the host to selectively absorb nutrients via enzymes located in
the brush border of the villi that characterize intestinal microstructure. The impediment also
separates the host from the microbiome, a large repository of bacteria. Finally, organized
lymphoid centers (Peyer’s patches) provide immune surveillance of intestinal content.

Author Manuscript
Author Manuscript

Sepsis disrupts all of these functions. Peristaltic contractions may be “mistimed,” failing to
move ingested substrate forward, or may disappear altogether (“ileus”) (77). Tight junctions
are disrupted by mechanical forces and reduced expression of their constituent proteins.
Similar changes reduced absorption via brush border enzymes and induce villus atrophy. In
addition, epithelial cells are lost to necrosis/apoptosis and regeneration is limited. Overall
barrier function is reduced, allowing some intestinal debris and bacterial products access
into the lymphatics and the blood stream (77). Immune activity in Peyer’s patches mirrors
systemic effects; cytokine production is enhanced but engulfment and breakdown damaged
cells, proteins, or microorganisms are impaired (78). Sepsis itself, or the antibiotics used to
treat it, induce massive changes in the microbiome that Alverdy et al (80) have described as
a “pathobiome” (79). The impact of these changes (“dysbiosis”) on organ function and
survival are incompletely understood, highlighting an essential gap in our understanding of
sepsis (81, 82).
Intestinal motility, which is disrupted in sepsis, can be measured clinically via several
methods. The lactulose breath hydrogen test indirectly measures motility via quantification
of exhaled hydrogen, the product of lactulose metabolism by colonic bacteria. Manometry
may be used to measure pressure alterations at various points along the GI tract. Innovative
methods include wireless capsule technology, where ingestible capsules perform endoscopic
and other assessments of GI functionality (83).

Author Manuscript

GI absorptive capacity can be measured using a differential sugar absorption test, most often
using sucrose and xylose. Because D-xylose does not require enzymatic cleavage before
transport across the mammalian epithelium, the ratio of D-xylose to other sugars in blood
provides an index of absorption. Clinical studies in septic patients subjected to the xylose
absorption test suggest decreased absorption (84).
Epithelial integrity and barrier function of the GI are markedly decreased in sepsis.
However, separating dysfunction and injury is problematic because it is unclear if the
intestinal barrier can become leaky in the absence of actual damage. Barrier dysfunction can
be identified by the presence of bacterial products such as endotoxin or plasma D-lactate, a
fermentation product of intestinal bacteria, in the circulation (85–87). Injury to cells may be
reflected in high plasma and/or urine levels of epithelial cell proteins such as intestinal fattyShock. Author manuscript; available in PMC 2021 March 23.
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acid binding protein, whereas damage to tight junctions will elevate serum levels of
claudin-3 (85, 88). Serum zonulin, a regulator of tight junctions, has been measured in
patients with sepsis (89). A single study of 9 patients identified increased colorectal
permeability in patients using rectal administration of 51Cr-labeled ethylene diamine tetraacetic acid (EDTA) (90). This study has not been verified, and administration of other
markers used following CLP (see below) has not been reported in patients with sepsis.
Dysbiosis in patients with sepsis is characterized by a decrease in commensal
microorganisms with a concomitant rise in pathogenic strains. The extent of these
microbiomic alterations can be measured via fecal sampling and bacterial genomic
sequencing (91).
Measurable abnormalities following cecal ligation and puncture
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CLP significantly alters GI function in a manner that appears to resemble the changes seen
in clinical sepsis (92–94). Motility can be examined using intracolonic balloon-tipped
catheters or tracking of ingested solid beads (95, 96). Tests of absorption described in human
sepsis can be used following CLP. Multiple studies have demonstrated an increase in flux
across intestinal tight junctions following CLP. Orally administered fluorescein
isothyocyanate-conjugated-dextran (FD-4), or, less frequently, 51Cr-labeled EDTA or
ovalbumin have been detected in the blood following CLP (93, 97, 98). CLP also enhances
direct injury. For example, CLP decreased the abundance of the tight junction proteins
claudin-2, claudin-5, occludin, and JAM-A in intestinal wall samples (93, 99). Post-CLP
atrophy and shortening of villi may reflect decreased crypt proliferation and increased
epithelial cell apoptosis (100).
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Few studies have evaluated changes in the microbiome post-CLP. Chen et al noted that CLP
in wildtype mice caused a 25.87% increase in Bacteroidetes abundance and a 36.68%
decrease in Firmicutes abundance, along with significant alterations in other phyla (101).
The use of antibiotics that altered the microbiome led to a significant increase in CLPinduced mortality. It should be noted that microbiome profiles vary greatly on the basis of
the vendor providing the animals and may also be altered by diet (102).
Correlations between changes induced by clinical sepsis and cecal ligation and puncture
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Although GI dysfunction can be assessed in clinical sepsis and following CLP, only a
limited number have been used in both. Motility measurements in each condition are quite
different and what is useful in 1 may not be appropriate for the other (84, 95, 96). Similarly,
although clinical tests measuring absorption of sugars or food coloring can be used
following CLP, more precise measurements can be made via administration of fluorescent or
radiolabeled molecules. Clinical administration of radiolabeled substances such as 57Cr
EDTA is problematic in the US, whereas FD-4 has not been evaluated in patients. Although
biomarkers indicative of tight junction or cellular injury can be identified in the blood of
patients, CLP affords the opportunity to determine their abundance directly in intestinal cell
homogenates or fixed tissue samples. This approach is clinically viable only in biopsy or
postmortem analyses.
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Microbiomic alterations can be determined in septic patients and post-CLP using 16S rRNA
sequencing, shotgun metagenomics, or other techniques. Thus, a more direct comparison of
microbiome homeostasis between CLP and clinical sepsis is possible. However, the
endogenous flora of the 2 species may be markedly different, requiring comparison based on
similarities (eg, gram-negative bacteria, anerobes).
Recommendations
Despite current limitations on the clinical use of methodology that has been immensely
valuable in animals, taking full advantage of the opportunities to examine intestinal
dysfunction/injury available following CLP appears to be advisable. Should novel clinical
methods be developed, the availability of robust data on intestinal dysfunction/injury
following CLP will enable comparisons. Complete GI evaluation following CLP might
include the following
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•

Intestinal integrity using xylose absorption.

•

Barrier function should be examined via measurement of
–

Serum/urine levels of bacterial products (eg, endotoxin), claudin-3,
intestinal fatty binding protein, or D-lactate

–

Administered D-xylose or Blue Dye #1

•

Motility can be assessed using solid beads

•

Measures of barrier function that cannot be performed in patients, at least at this
time, should be considered. These might include:
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•

–

tight junction proteins (claudins, occludin, JAM-A) abundance in tissue
homogenate or sections

–

serum levels of orally administered FD-4 or 57Cr EDTA

Performance of bacterial genomic sequencing to identify changes in the
microbiome in colonic samples

LIMITATIONS AND CAVEAT
Concerns regarding the current lack of tests that can be used in both patients with sepsis and
following CLP have been discussed. The normal microbiota in humans and rodents are
different and either may be affected by factors other than sepsis. Further, differences in diet,
endogenous flora, and other conditions across studies might have bearing on the results.
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BRAIN DYSFUNCTION FOLLOWING CECAL LIGATION AND PUNCTURE
Clinical presentations/quantifiable measures of organ dysfunction/injury in patients with
sepsis
Brain dysfunction in sepsis takes the form of either acute septic encephalopathy (ASE), a
catchall that encompasses a diverse array of behavioral and cognitive abnormalities (103), or
more chronic and lingering abnormalities. Alterations in consciousness may range from
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confusion and disorientation to delirium to deep coma. Seizures and focal neurological signs
have also been reported (103). The most commonly invokes state is described as
“hypomanic delirium”. Diagnosis is complicated by the frequent use of neuropharmacologic
agents. Sepsis survivors report that ASE is associated with vivid nightmares, hallucinations,
and paranoid delusions, whereas chronic issues include lingering delirium, PTSD, and
significant declines in memory and attention (7). Sepsis survivors are at increased risk to
develop dementia (104). Both ASE and dysfunction in long-term sepsis survivors are
associated with increased mortality (105).
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Acute alterations in consciousness in the ICU have been evaluated with neuropsychological
testing, in particular, the Confusion Assessment Method for the ICU (106) and the Intensive
Care Delirium Screening Checklist (107), 2 tools that were specifically developed to
evaluate the level of consciousness in critically ill patients. Sepsis-induced EEG
abnormalities include θ waves, Δ waves, triphasic waves, periodic epileptiform discharges,
electrographic seizures, and generalized or burst suppression (103). Abnormalities in MRI
scans have also been reported (108).
Measurable abnormalities following cecal ligation and puncture
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The ability to collect pathological specimen and perform more involved functional tests has
produced an understanding of CLP-induced abnormalities specific to the brain that exceed
what has been identified in clinical sepsis. In the first week post-CLP, activation of the
orexinergic and basal forebrain cholinergic systems was reduced (109, 110). There is
evidence of neuroinflammation (increased cytokine abundance, neutrophil infiltration,
inflammasome activation) and oxidative damage (increased nitrite/nitrate ratio, lipid
peroxidation, carbonyl protein formation, decreased activity of antioxidants) and reduced
expression of brain-derived neurotropic factor (110–113). The blood–brain barrier is
disrupted (112). Structural abnormalities include shrunken cell bodies, nuclear pyknosis and
cellular degeneration of hippocampal pyramidal neurons (111,113), reduction in length and
density of dendritic spines in the CA1 and CA2 regions of the hippocampus and in the
amygdala have been noted in long-term CLP survivors (12, 114). Limited EEG data suggest
reduced EEG delta power density during nonrapid eye movement sleep (115). MRI imaging
post-CLP has revealed findings consistent with cytotoxic and vasogenic edema and neuronal
damage (116, 117).
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Both short and long-term behavioral changes are of particular importance when examining
correlations between human sepses. Abnormalities following CLP include evidence of
anxiety and depression-like symptoms (11, 118), impairments in locomotion, spacial and
contextual-fear memory, fear conditioning and adversive learning (11, 12, 111, 113, 114,
118).
Correlations between changes induced by clinical sepsis and cecal ligation and puncture
Identifying correlations sepsis-induced defects in brain function and changes following CLP
is problematic. MRI studies in humans are too limited for comparison and changes in EEG
δ-waves are nonspecific. Some structural lesions observed following CLP may reflect
ischemia/hypovolemia only. Although histologic changes and evidence of
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neuroinflammation have been consistently noted following CLP, similar findings are
unlikely to be identified in humans. Short-term behavioral changes have been noted in both
septic patients and in rodents during the first-week post-CLP. Limited mobility and lack of
response to environmental stimuli following CLP may well represent the murine equivalent
of the delirium, agitation and terrifyingly vivid hallucinations and delusions that characterize
human hypomanic depression but differences between species make comparisons difficult.
The use of drugs that affect the brain in general and that specifically alter behavior in both
human sepsis and post-CLP mice further complicates matters. Better correlations may be
present when comparing long-term behavioral changes because post-CLP memory
impairment is likely the equivalent of cognitive impairment in sepsis survivors, changes in
fear conditioning may be analogous to PTSD and depression can be quantitatively assessed
in both patients and mice.
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Recommendations
As in previous sections, recommendations reflect the ability to currently correlate sepsis and
CLP-induced changes and the possibility that advances in the future will enable correlations.
We therefore suggest the following studies be considered in rodents subjected to CLP
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•

Histologic and immunohistochemical analysis of fixed brain tissue.

•

Measures of neuroinflammation, including cytokine abundance and evidence of
oxidative stress in different regions of the brain

•

Assessment of changes in movement and responses to external stimuli, which
may be analogous to human hypomanic depression.

•

Changes in MRI scans.

•

Measurement of quantifiable indices of memory loss and mood in long-term
survivors of CLP.

LIMITATIONS AND CAVEATS
Some rodent measurements are limited to assessing movement and memory recall of
movements. The caveat here is not to parallel that degree of mobility lost or lack of recall
with clinical manifestations of memory, mood, anxiety, and depression disorders.

SKELETAL MUSCLE DYSFUNCTION FOLLOWING CECAL LIGATION AND
PUNCTURE
Author Manuscript

Clinical presentations/quantifiable measures of organ dysfunction/injury in patients with
sepsis
Skeletal muscle accounts for more than 50% of body cell mass and thus represents the
largest organ affected by sepsis. All forms of “stress’/inflammation deplete skeletal muscle,
which serves as a source of amino acids for gluconeogenesis and tissue repair (119). More
importantly, critical illness in general and sepsis in particular are associated with intensive
care unit acquired weakness (ICUAW), a catch-all term that encompasses 2 entities, critical
illness myopathy and critical illness polyneuropathy (CIP), that are difficult to separate
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(120). The reported incidence of ICUAW varies widely on the basis of the underlying
condition and the duration of ICU stay (121, 122). Risk factors include mechanical
ventilation, immobilization, sepsis, multiple organ dysfunction, and the use of myotoxic/
neurotoxic medications (eg, neuromuscular blocking agents and corticosteroids) (122, 123,
125). ICUAW is characterized by flaccid, symmetrical weakness that is more pronounced in
proximal muscle groups. Deep tendon reflexes may be normal or reduced. When CIP is a
component of ICUAW, reduced sensation to pain and temperature may be present. ICUAW
may interfere with weaning from the ventilator (124) and may persist following recovery
from sepsis, leaving survivors with persistent weakness (120, 125).
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Guidelines for studying ICUAW in septic patients suggest the use of several functional
modalities. Bedside assessment of muscle strength may be quantified using the Medical
Research Council (MRC) sum score (120, 126), which evaluates strength in 6 muscle
groups. An MRC score of less than 48 is consistent with a diagnosis of ICUAW (127). MRC
score may be complemented by handgrip strength (123). The final recommendation is
determination of maximal inspiratory pressure, which has been associated with the duration
of weaning from the ventilator (123,128). Muscle excitability during needle
electromyography (EMG) is characteristically reduced (129, 130). Elevations of serum
creatine phosphokinase (CPK) levels, which have been inconsistently documented, provide
evidence of muscle injury as do the results of muscle biopsy, which, when performed,
characteristically demonstrates a loss of myosin filaments, axonal degeneration and tissue
necrosis (131). Finally, mitochondrial number may be reduced, whereas decreased ATP
(Adenosine Triphosphate) production likely reflects decreased activity of electron transport
chain (ETC) complexes I and IV (132). An increase in the number of damaged mitochondria
suggests both direct injury and dysfunction in the processes responsible for mitochondrial
removal (mitophagy) and regeneration (biogenesis) (132). It has been suggested that both
dysfunction and injury result from inflammation because tissue levels of IL-1, IL-6, IL-10,
and TNF-α are elevated (133–135).
Measurable abnormalities following cecal ligation and puncture
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Locomotor activity in rodents subjected to CLP is reduced and the animals assume an
abnormal posture (136). As in human sepsis, CPK levels are inconsistently elevated,
suggesting variable degrees of actual muscle injury. Isolation and direct stimulation of
individual motor units in rats post-CLP showed a prolonged muscle contraction time and a
reduced maximal muscle force (136, 137). Both primary data and extrapolation from studies
on diaphragmatic or cardiac muscle have demonstrated profound reductions in
mitochondrial content, whereas function as reflected in a reduction in mitochondrial
membrane potential and dysfunction in all 4 ETC complexes, is also decreased (138, 139).
As in human sepsis, CLP is characterized by mitochondrial injury, reflected in an increased
number of damaged mitochondria and impaired autophagy and biogenesis (140). In addition,
cytokine elevations similar to those observed in septic humans have been identified (133–
135).
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As detailed above, functional changes characteristic of ICUAW in both patients with sepsis
and in rodents following CLP include prolonged contraction time and force, abnormalities
on EMG, and changes in the number and activity of mitochondria, including reductions in
the activity of electron transport complexes I and IV (141, 142). Injury is reflected in muscle
proteolysis and, inconsistently, CPK elevations (119, 143). However, although ICUAW
preferentially affects myosin filaments in human sepsis (131), myosin, and actin are equally
affected in rodents subjected to CLP (144).
Recommendations
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In contrast to a number of other organ systems, dysfunction in patients with sepsis and
rodents subjected to CLP are similar, enabling direct comparisons. Therefore, we suggest
that the following measurements be considered following CLP
•

Assessment of motor activity including postural instability

•

CPK levels

•

Cytokine abundance in muscle homogenate

•

Histologic analysis and quantification of filament loss, mitochondrial number,
and biogenesis/mitophagy

•

Muscle levels of high-energy phosphate intermediates, mitochondrial respiration,
mitochondrial DNA (biogenesis), and ETC complex activity

•

Myography (despite potential difficulty in performing the test)

Author Manuscript

LIMITATIONS AND CAVEATS
An important caveat in all proposed measures is that myopathy has only been studied in the
acute phase post-CLP, whereas ICUAW is most often examined as a chronic condition in
patients weeks or even months after recovery from critical illness (123, 143).

GLOBAL LIMITATIONS, CAVEATS, AND CONCLUSION
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In this document, we have outlined indices of organ dysfunction that we believe should be
used as outcome measures in assessing rodents subjected to CLP. This approach is consistent
with the recent revised definition of sepsis (Sepsis-3), which stresses the importance of
organ dysfunction as the key characteristic of sepsis (13). We believe that the use of these
proposed measures will facilitate mechanistic studies into the pathobiology of sepsis and
enhance our ability to use CLP as a platform to evaluate therapeutic approaches to the
human disorder.
There are several key limitations to recommendations made in this article. Perhaps the most
important lies in this review’s focus on CLP in rodents. It is clear that reliance on CLP is
problematic, despite the fact that recent studies indicate that it is the most frequently used
animal model of sepsis (145). CLP differs from human sepsis in a substantial number of
ways that may well limit its utility as a platform for pre-clinical testing of potential therapies
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(6). Although the translational failure of therapeutic approached developed using CLP is 1
justification for recommending that indices of organ dysfunction be used as endpoints, it
may not be the most important. Indeed, it has been argued that the primary value of CLP is
“reductionist”, lying in its use to answer specific questions. We suggest that such a specific
question might be “What mechanisms underlie sepsis-induced dysfunction in (fill in the
organ your organ of choice)?”
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We posit that the use of mortality as an endpoint is problematic for 2 reasons; recent work
suggests that it may not be possible to completely eliminate mortality from human sepsis
(146), and rodents are far more tolerant than humans of insults that lead to sepsis (147). The
other endpoint commonly used in studies using CLP involves changes in immune function.
This approach is also problematic: clearly, immune dysfunction is not the only form of organ
impairment in sepsis; whereas changes in immune function may lead to organism-wide
abnormalities, the same can be said of alterations in the endocrine and neuronal systems,
which are also profoundly altered early in the course of sepsis (116, 148); and interventions
designed to correct sepsis-induced immune dysfunction have failed to improve outcomes
(149).
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We acknowledge that CLP in rodents is just 1 of many animal models of sepsis. However, an
exhaustive recent review of the literature documents that, in spite of its’ many limitations, it
is by far the most commonly used. Indeed, pneumonia is now the most common source of
human sepsis (150), accounting for the increasing use of models of lung infection in model
systems (93). CLP has many drawbacks, some of which we have identified when reviewing
parameters in individual systems. We recognize that what constitutes “organ dysfunction” in
mice and rats subjected to CLP may differ substantially from what characterizes “organ
dysfunction” in human sepsis. However, although the actual manifestations of organ
dysfunction differ between mice and men, organ dysfunction is, in general, present in both.
Mice subjected to CLP develop hypothermia, bradycardia, and a reduced respiratory rate,
whereas septic humans, at least initially, become febrile, tachycardic, and increase their
minute ventilation. But both develop impaired thermoregulation, myocardial contractility,
and hypoxemia. Differences in the response of the murine immune system following CLP to
those observed in human sepsis have been a key point raised by those who do not believe
that mice can be used to model the clinical disorder (6). However, that the immune system
becomes dysregulated in both is undisputed. What is key is that there is dysfunction, not the
specific manner in which dysfunction manifests itself. We would also point out that not all
patients with sepsis exhibit every possible form of organ dysfunction.
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We recognize that organ dysfunction in sepsis and following CLP is affected by many
additional factors. Manifestations of organ dysfunction may be altered by systemic
influences, particularly those resulting from variable degrees of resuscitation or from the
influences of both the endocrine and immune systems. Indeed, we have not included either
of those systems because both have been reviewed many times (148, 151) and organ
dysfunction in either is best recognized on the basis of their interactions with other systems.
Perhaps more importantly, conditions that are frequently identified as “comorbidities” have
dramatic effects on both clinical sepsis and sepsis-like approaches such as CLP. That age is a
determinant of both responses and outcome in both sepsis and following CLP is
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unquestioned (152–154). The effects of disorders such as diabetes are more problematic;
studies on diabetes have yielded conflicting results such that the impact of the disorder on
sepsis outcomes requires further investigation (155, 156). An additional confounder that is
implicit but not discussed in detail is the effects of sedations in patients or the need for
anesthetics in animals. In addition, we have not included a discussion of vascular
dysfunction because it is not readily measured in patients.
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There are 2 additional issues regarding the use of CLP that require comment. First, an
advantage of this model is that it makes the use of isolated perfused organ preparations
possible. Indeed, it was use of this approach that first identified the CLP-induced relative
resistance of cells to endocrine stimulation (43, 47). In addition, although there are clear
differences between rats and mice, the response to CLP in each is similar. There are 2
important differences that may dictate choice of 1 over the other. The development of
transgenic animals is most advanced in mice, whereas the larger size of rats, and in
particular, their larger blood volume may enable multiple blood sampling in a single animal,
making serial measurements possible.
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We have also attempted to distinguish between “dysfunction” and “injury.” The distinction is
important; structural damage may have no impact on function, and functional abnormalities
may not be reflected in demonstrable damage. Difficulty in separating these 2 entities is
often problematic. In some instances, dysfunction independent of injury is easily identified
(eg, using ECHO to identify reduced myocardial contractility). Most often, however, some
surrogate or proxy for abnormal function is used (eg, oxygen content in the blood,
inadequate bilirubin detoxification/elimination by the liver, creatinine clearance by kidneys).
At times, these proxies reflect actual injury and not dysfunction (eg, hypoxemia because of
lung injury, biomarkers like KIM-1 used to identify AKI). In some cases, they may be too
sensitive to actually use (eg, hepatic transaminases, cardiac troponin). Changes in proxies
may also be affected by some of the systemic abnormalities previously mentioned.
Ultimately, dysfunction must reflect injury on some level (eg, tubular injury in AKI, which
likely underlies dysfunction), even if that injury is readily reversible.
Finally, we reiterate that murine CLP is at best a proxy for human sepsis, and not a true
model of the disorder. Our attempt to identify measures of organ dysfunction or injury in
CLP, and to correlate those measures with similar abnormalities in human sepsis, reflects a
desire to encourage the use of organ dysfunction as the most appropriate outcome variable.
We hope that this change, which is consistent with the current definition of sepsis, will
improve our ability to translate findings from animal models to human sepsis.
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Table 1 contains a referenced summary of all suggestions.
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Liver

Lung

Heart

Organ System

Y
Y
Y
Y

LVESP
PAP
Strain
Fractional shortening

Y

Y

Y

Transthyretin

Y

Y

Transferrin

Impaired gene expression (42–45, 47)

Y

Albumin

Y

Y

Decreased hepatic protein synthesis

Y

Cytokine levels

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Has been determined in mice/rats following cecal
ligation and puncture

MPO (33)

Tissue homogenate

hyaline membrane

proteinaceous exudate

Neutrophils

Edema

Fixed tissue analyses (33)

Y

Y

LVESV

Y

Y

LVEDP

Cell counts/protein (BAL)

Y

LVEDV

Lung water/wet/dry ratio (35)

Y

EF

Y

Y

PaO2; PaO2/FiO2 ratio

Y

SV

Has been determined in clinical sepsis

HR

Echocardiographic abnormalities (21)

Measurements/Tests

Organ system specific abnormalities in human sepsis and following cecal ligation and puncture
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Gastrointestinal tract

Kidney

Author Manuscript
Y

GFR (73)

Y
Y

Cystatin-C
Transcutaneous measurements

Y

TIMP2
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Occludin

Claudin-5

Claudin-2

Tight junction proteins (93, 99)

Crypt atrophy, villus shortening/atrophy, intestinal apoptosis (100)

Histology

Microbiome composition (101)

FD-4, EDTA, Ovalbumin (93, 97, 98)

Mucosal barrier integrity

Ingestion/tracking of solid beads

Intracolonic balloon-tipped catheters

Y

Y

Y

Y

NGAL
Motility (83, 95, 96)

Y

KIM-1

Tubular injury markers (70, 76)

Y

IGFBP7

Tubular stress markers (71)

Y

Creatinine

Inulin

Y

Y

Y

Y

Y

RBF (74, 75, 76)

Urine output

Abnormal bile acids (41)

AST, ALT

Decreased cellular integrity

Decreased lidocaine clearance

Increased bilirubin

Impaired detoxification (49, 50, 51)
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Y

Y

Y

Y

Y

Y
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Y
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Memory, learning, behavior (11, 12)

TNF-α

IL-10

IL-6

IL-1

Tissue cytokine levels (133–135)

Y

Y

Y

Myography (129, 130)

Y
Y

Y

Y

Impaired mitochondrial membrane potential (138, 139)

Y

CPK elevation

Y

Total mitochondrial content (138)

Y

Postural instability (136)

MRI (116, 117)

EEG (115)

Hippocampal staining Dendritic spines (12)

Basal forebrain staining Cholinergic activity (110)

Lateral hypothalamic staining Orexinergic activity (109)

Y

Y

Y

Has been determined in mice/rats following cecal
ligation and puncture
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Y denotes YES

CPK, Creatine phosphokinase; EDTA, ethylene diamine tetra-acetic acid; EF, ejection fraction; FD-4, fluorescein isothyocyanate-conjugated-dextran; GFR, glomerular filtration rate; HR, heart rate;
IGFBP7, insulin-like growth factor-binding protein-7; KIM-1, Kidney Injury Molecule-1; NgAL, neutrophil gelatinase-associated lipocalin; NGAL, neutrophil gelatinase-associated lipocalin; PAP,
pulmonary artery pressure; RBF, renal blood flow; TIMP2, tissue-inhibitor of metalloproteinases-2.

Skeletal muscle

Y

Anorexia

Fixed tissue analyses:

Y

Lethargy

JAM-A
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Brain
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Berlin Criteria for ARDS (25)
R = P AO2 /FiO2

PEEP

Mild

300 > R > 200

≥5

Moderate

200 > R > 100

≥5

R < 100

≥5

ARDS Severity

Severe

ARDS, Acute respiratory distress syndrome.
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